Juanbadimon
@juanbadimon
Followers
129
Following
26
Media
4
Statuses
20
Professor of Medicine. Director of the Atherothrombosis Research Unit at the Cardiovascular Institute. The Mount Sinai School of Medicine.
New York, NY
Joined October 2020
Hear hear! Reducing endomyocardial biopsies in heart transplant surveillance will improve quality of life of patients! Plus @JeffTeuteberg as a person is amazing!.
So thrilled to have the extraordinary and amazingly talented clinician @JeffTeuteberg as our Visiting Professorship at @MountSinaiHeart.Leading the change for biomarkers to replace cardiac biopsy in cardiac transplant surveillance.@DLBHATTMD @dranulala @spinneymd @DonnaMancini11
0
0
4
RT @SantosGallegoMD: What a tour de force by the amazing @PamTaubMD as Visiting Professor at @MountSinaiHear!.She masterfully took us throu….
0
5
0
RT @SantosGallegoMD: Wow! An SGLT2i is sold at $47.85!!!! (shipping included) 🥳🍾🎉🤑💸.That is 8% of the going price of empagliflozin or dapag….
fiercepharma.com
As another SGLT2 diabetes drug hits the market, the obvious question is: How will it find a way to compete against formidable blockbusters Farxiga and Jardiance? | TheracosBio and Mark Cuban's online...
0
23
0
Are the benefits of sotatagliflozin observed in T2DM also present in non-diabetic HFpEF? .Be patient and wait for the results of the ongoing SOTA-P-CARDIA trial!!.@SantosGallegoMD @RequenaIbanez @Capijorge1 @MaeveSoto .
link.springer.com
Cardiovascular Drugs and Therapy - Heart failure with preserved ejection fraction (HFpEF) is now the most common form of heart failure (HF). This syndrome is associated with an elevated...
Nuevo artículo de la colaboración 🧑⚕️@capijorge en el grupo Icahn School of Medicine @juanbadimon @SantosGallegoMD @RequenaIbanez . Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes .@SpringerCardio.
1
5
7
RT @SantosGallegoMD: I have learnt so many concepts about RV evaluation from thr master himself, the one and only @RyanTedfordMD, in the Gr….
0
13
0
Should we consider increased ketone body levels as one of the mechanisms of action involved in the cardiorenal benefit of SGLT2i?. Our recent article supports this concept! @santosgallegoMD @RequenaIbanez. @dlbhattmd @IcahnMountSinai @SinaiCards.
2
21
57
Everything you wanted to know about the CLEAR-Outcomes trial, but were afraid to ask. Read my view on the latest @secardiologia blog entry. LDL, the lower the better, the earlier the better!. @lipidmir @ResiSec #cardioed #meded @Capijorge1
3
15
48
Completely agree with this statement (also including history, imaging, . ).
With every passing day I learn that @SantosGallegoMD is an expert on another topic (SGLT2i, Spanish wine, opera, Futbol, tapas, bourbon…the list is endless). @rachkataria and @JonathanDavisHF decided that he is the most interesting man in the world. (#AHA22 edition)
0
0
4
RT @SantosGallegoMD: Great pairing with this tweet by the great @gcfmd . "What does this say about discharging a HFrEF patient without ARNI….
0
6
0
RT @SantosGallegoMD: So honored to be able to offer my perspective about the benefits of SGLT2i in heart failure in this article by the gre….
tctmd.com
HF hospitalizations were reduced in all patients, yet only the higher-risk diabetic patients gained the survival advantage.
0
18
0
SOTA-P-CARDIA will be the first trial to specifically enroll patients with the new HFpEF definition (LVEF>50%). Previous trials used a threshold of LVEF>40%; thus enrolling both HFmrEF and "true" HFpEF patients . @gcfmd @andrewjsauer @christos_argyrop @acorderofort @almucastro01
1
2
18
SGLT2i improve hard endpoints in HFpEF. Will the dual SGLT2/1 inhibitors also improve HFpEF?.Rationale .1)SGLT1/2i are more potent metabolically than SGLT2i .2)SGLT1-R are over-expressed in failing myocardium .3)SOLOIST showed the benefits of sotagliflozin in both HFrEF&HFpEF.
1
0
2
I am proud to announce that we are initiating our SOTA-P-CARDIA trial investigating the effects of the dual SGLT1/2 inhibitor sotagliflozin on HFpEF patients.@requenaibanez @santosgallegoMD @mountsinaiheart @anulala @sumeetmitter @jcontreras75 @dlbhattmd.
3
13
38
Hear, hear!.
This is why we cannot trust unplanned unpowered subgroup analysis. Essential info for anyone who wants to do a post-hoc, non-protocol specified subgroup analysis (fishing expedition). If you look at enough subgroups, you will find one with a “statistically significant” difference.
0
0
0
Absolutely true! Statistics are basic for science. Randomization always superior to propensity-score matching.
Biostatistics made easy. The truth about propensity score matching.@ChristosArgyrop @gmsamaras @mikejohansenmd @JJheart_doc @RezaMohebiMD @hvanspall @AndrewJSauer @scoca1 @girish_nadkarni @almucastro01 @acorderofort @ShelleyWood2 @mvaduganathan @docbhardwaj @CVCTForum @samtori
0
0
3
RT @SantosGallegoMD: A real honor to give the Opening Lecture at this HFpEF conference! .Very comprehensive program and a stellar group of….
0
5
0
That is why research is essential: to discover new drugs!. That is why research is the great equalizer: if your methods are solid and your discovery is important, it does not matter whether you are a second-year med student or a full professor.
A 2nd-year med student published as single author the discovery of heparin today 106 years ago. Isolated from canine liver (“hepar” or "ήπαρ"="liver" in Greek).@ChristosArgyrop @AndrewJSauer @gcfmd @CMichaelGibson @Drroxmehran @CardioNerds @MKIttlesonMD
0
0
0